


XTEND-1 study design



Adapted from von Drygalski A, et al. 2023.⁶

*ABR during the ALTUVOCT once-weekly prophylaxis treatment period (Arm A) vs ABR during pre-study prophylaxis in a subgroup of patients from the 12-month observational pre-study.⁴